Back in December 2017, Pfizer started a trial to explore whether the PARP inhibitor talazoparib (Talzenna) could be used in combination with enzalutamide (Xtandi) to effectively treat men with what are known as MSI-H or dMMR subtypes of metastatic castration-resistant prostate cancer (mCRPC). Studies a U.S. FDA-regulated Drug Product: Studies a U.S. FDA-regulated Device Product: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. Patients may have in the past are also excluded. Current or anticipated use within 7 days prior to first dose of study drug or anticipated use during the study of the following P gp inhibitors (amiodarone, carvedilol, clarithromycin, cobicistat, darunavir, dronedarone, erythromycin, indinavir, itraconazole, ketoconazole, lapatinib, lopinavir, propafenone, quinidine, ranolazine, ritonavir, saquinavir, telaprevir, tipranavir, verapamil, and valspodar). 13. Known or suspected brain metastasis or active leptomeningeal disease. The drug, which Pfizer gained access to after it bought Medivation in a $14 billion deal last year, generated global sales of more than $600 million in the April-June period. The research report is an overall draft when it comes to understanding the investment structure and… 8. melanoma. It is the second deal between Pfizer and a prostate cancer drug developed by Myovant CEO Dr. Lynn Seely. historical testing (with Sponsor approval) using the Foundation Medicine, Pfizer’s shares were up 1.8 percent as an approval to expand the use of the drug could significantly boost sales. investigational agent within 4 weeks before day 1. Serum testosterone ? not have access to these therapies. Pfizer Oncology is striving to change the trajectory of cancer. Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (TSE:4503) today announced the Phase 4 PLATO study, evaluating the efficacy and safety of continued treatment with XTANDI® (enzalutamide), plus abiraterone acetate and prednisone as compared to treatment with abiraterone acetate and prednisone alone, did not meet its primary endpoint of improvement in progression-free survival (PFS) … language Sort by. 6. Order. Myovant and Pfizer will begin co-promoting ORGOVYX for advanced prostate cancer in early 2021. About Astellas contraception as outlined in this protocol for the duration of the study and for at Today, Pfizer Oncology has an industry-leading portfolio of 22 approved innovative cancer medicines and biosimilars across more than 30 indications, including breast, prostate, kidney and lung cancers, as well as leukemia and melanoma. The purpose of this international, phase 2, open-label, response rate study of talazoparib is to assess the efficacy and safety of talazoparib in men with DNA repair defects metastatic castration-resistant prostate cancer (CRPC) who previously received taxane-based chemotherapy and progressed on at least 1 novel hormonal agent (enzalutamide and/or abiraterone acetate/prednisone). contraception must be used from the time of the first dose of study drug through 4 acetate/prednisone). A place to seek and offer support, ask questions, share information and chat about personal experiences of prostate cancer. 12. Major surgery within 2 weeks before day 1. 7. ATLANTA, Jan. 27, 2020 /PRNewswire/ -- The American Cancer Society and Pfizer have approved grants totaling more than $2.5 million in nine communities focused on reducing racial disparities and helping optimize outcomes for women facing a breast cancer diagnosis. study participation. Share your location or enter your city or zip code to find studies near you. Pfizer Inc. confirmed that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application to treat prostate cancer. It has long been suggested that talazoparib may be the most active… Must use a condom when having sex from the time of the first dose of study drug through 4 months after last dose of study drug. castration). In this particularly personal episode of The Doctors, Dr. Freda Lewis-Hall shares the signs & symptoms of prostate cancer- the second most common cancer in men worldwide. In the EU alone, 78,800 men died of prostate cancer last year. Must agree not to donate sperm from the first dose of study drug to 4 months after the last dose of study drug. ... 205 participants that included 54 healthy volunteers and 151 older patients with either solid cancers such as breast or prostate cancer and those with hematological, or blood cancers, such as leukemia. A highly effective form of contraception must be used from the time of the first dose of study drug through 4 months after last dose of study drug when having sex with a non pregnant female partner of childbearing potential. 17. Radiation therapy within 3 weeks (within 2 weeks, if single fraction of radiotherapy) Must use a condom when having sex from the time of the first dose of study drug with study participation or investigational product administration or may interfere Known or suspected brain metastasis or active leptomeningeal disease. The purpose of this international, phase 2, open-label, response rate study of talazoparib is According to the American Cancer Society, more than 161,000 men are estimated to be diagnosed with prostate cancer this year in the United States. Ongoing bisphosphonate or denosumab use prior to Day 1 (Part 1) or randomization (Part 2) is allowed but not mandatory. meningitis causes. The grants, funded by Pfizer … 5. (Reuters) - Pfizer Inc and Japan’s Astellas Pharma Inc said on Thursday their blockbuster prostate cancer drug met the main goal of a key study that tested it for treating the disease in its early stages. Clinically significant cardiovascular disease. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: Histologically or cytologically confirmed adenocarcinoma of the prostate without signet cell, or small cell features. 12. 6. investigator or sponsor, including recent (within the past year) or active suicidal Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. causes undue risk, or complicates the interpretation of data, in the opinion of the 4 weeks or 5 half lives of the drug (whichever is longer) before Day 1 and/or during Myovant Sciences - Get Report was higher Monday after the biopharma and Pfizer - Get Report said they would collaborate on a prostate-cancer … Myovant Soars on $4.2 Billion Pfizer Prostate-Cancer Deal. Though we weren’t able to gather physically for this year’s ZERO - The End of Prostate Cancer Run/Walk Prostate Cancer Awareness Month events … The drugs, both PARP inhibitors, are approved to treat men whose cancers have stopped responding to hormone treatments and have specific genetic alterations that affect DNA repair, including BRCA mutations. Contact a representative by phone, email, or visiting the study website. prostate cancer or nonmetastatic (M0) CRPC. Prior diagnosis of myelodysplastic syndrome or acute myeloid leukemia. Call or email to reach a Pfizer Clinical Trial Contact Center Representative. About Pfizer: Breakthroughs That Change Patients’ Lives. - Soft tissue disease progression as defined by RECIST 1.1. Patients who discontinued prior platinum based chemotherapy <=6 months prior to FoundationOne CDx™ NGS gene panel test. Progressive disease at study entry defined as 1 or more of the following 3 criteria: Copyright © 2002-2021 Pfizer Inc. All rights reserved. Patients must have measurable soft tissue disease per RECIST 1.1. Shares of Myovant Sciences soared 27% Monday, after its parent Sumitovant Biopharma unveiled an agreement with Pfizer Inc. to jointly develop a treatment for prostate cancer … Patients who discontinued prior platinum based chemotherapy <=6 months prior to screening or whose disease previously progressed on platinum based therapy at any time in the past are also excluded. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1. John Lauerman; Bookmark. Clinically significant cardiovascular disease. News / Prostate Cancer Pfizer Global Health Topics. 13. Gastrointestinal disorder affecting absorption. Myovant shares gained as much as 35% on Monday after announcing a partnership with Pfizer to develop and commercialize a relugolix drug for the treatment of prostate cancer patients. The products discussed herein may have different labeling in different countries. The American Cancer Society and Pfizer Launch Community Grants Focused on Reducing Prostate Cancer Disparities Among Black Men March 3, 2021 GMT ATLANTA, March 3, 2021 /PRNewswire/ -- The American Cancer Society and Pfizer Global Medical Grants are collaborating and have awarded a new competitive grant opportunity focused on addressing prostate cancer disparities impacting Black men. Documented disease progression (either radiographic or biochemical) on at least 1 9. laboratory tests and other study procedures. 7. The positive data sets the stage for an earlier-than-expected approval of the drug, which is already cleared to treat metastatic castration-resistant prostate cancer (CRPC) - where the cancer has spread to other parts of the body. Estimated life expectancy of ? 5 Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Center (CNIO), Madrid/ES; 6 Medical Oncology, Peter MacCallum Cancer Centre, Melbourne/AU; 7 Drug Development Department, Institut Gustave Roussy, 94805 - Villejuif/FR; 8 Department Of Breast And Medical Oncology, National Cancer Center Hospital East, 277-8577 - Chiba/JP Our Standards: The Thomson Reuters Trust Principles. Bisphosphonate or denosumab dosage must have been stable for at least 4 weeks before day 1 for patients receiving these therapies. Estimated life expectancy of ≥ 6 months as assessed by the investigator. Patients must be willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures. médico Pfizer. meningococcal vaccine. The positive Xtandi trial comes three months after data showed Johnson & Johnson’s rival drug, Zytiga, reduced chances of death for men newly diagnosed with high-risk prostate cancer that had spread to other parts of the body. At present, physicians cannot predict drug response or therapy resistance in patients. 10. Treatment with any concurrent cytotoxic chemotherapy or investigational drug(s) within 1. There is no FDA-approved treatment for non-metastatic CRPC, according to Deutsche Bank analysts. ET ideation or behavior or laboratory abnormality that may increase the risk associated The factors, or reasons, that prevent a person from participating in a clinical study. The countries granted access include 11 low- and middle-income markets in the WHO Western Pacific area, which has the highest cancer mortality rate in the world, Pfizer stated. local regulations or ethics committee (EC) decision. Current or anticipated use within 7 days prior to first dose of study drug or 1. The U.S. Food and Drug Administration has approved Pfizer and Astellas Pharma's Xtandi to treat patients with a type of prostate cancer, the companies said on … Pfizer and Astellas jointly sell Xtandi in the United States, while Astellas owns the rights to develop and sell Xtandi outside the United States. “(This) data will serve as an important catalyst for Xtandi, while also improving sentiment on the Medivation deal,” Credit Suisse analysts wrote in a research note. Gastrointestinal disorder affecting absorption. Serum testosterone ≤ 1.73 nmol/L (50 ng/dL) at screening. determinations. Search for Clinical Trials by condition, keyword or trial number. Approximately $2 million USD is allocated to this research grants program focused on investigating talazoparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in prostate cancer. signet cell, or small cell features. Bone disease progression defined by Prostate Cancer Working Group 3 (PCWG3) with 2 or more new metastatic bone lesions on a whole body radionuclide bone scan. Progressive disease at study entry defined as 1 or more of the following 3 criteria: - A minimum of 3 rising PSA values with an interval of at least 1 week between All quotes delayed a minimum of 15 minutes. regimen for metastatic (non castrate or castrate) prostate cancer. Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or patients who are Pfizer employees, including their family members, directly involved in the conduct of the study. NGS gene panel test. before day 1. 8. Pfizer said the drug, Xtandi, in combination with an anti-hormone therapy, was statistically significant in improving survival in men with non-metastatic CRPC without their cancer spreading, compared with the standalone anti-hormone therapy. Fertile male subjects who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 4 months after the last dose of investigational product. Study: Pfizer Vaccine Offers Cancer Patients Less Protection After 1 Dose. indinavir, itraconazole, ketoconazole, lapatinib, lopinavir, propafenone, quinidine, 2. Discover how clinical trials work and the impact your participation could have. on bone scan. cancer that has a remote probability of recurrence in the opinion of the investigator Call or email to reach a Pfizer Clinical Trial Contact Center representative. 16. The factors, or reasons, that allow a person to participate in a clinical study. Pfizer Oncology is committed to discovering, investigating, and developing transformative therapies that improve the outlook for cancer patients worldwide. anticipated use during the study of the following P gp inhibitors (amiodarone, Ordinary vaccines tend to be inactivated or weakened viruses which, when injected into the body, stimulate an immune response that can later protect against the live pathogen partner of childbearing potential. The Prostate Cancer Foundation (PCF) and Pfizer, Inc. are proud to announce the PCF-Pfizer Global Challenge Awards, a competitive, peer-reviewed Investigator Sponsored Research (ISR) grants program. (testing of de novo or archival tumor tissue (via central laboratory) or prior Symptomatic or impending spinal cord compression or cauda equina syndrome. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Documented disease progression (either radiographic or biochemical) on at least 1 novel hormonal therapy (enzalutamide and/or abiraterone acetate/prednisone) for the treatment of metastatic CRPC, irrespective of prior NHT treatment for non castrate prostate cancer or nonmetastatic (M0) CRPC. FDA has approved olaparib (Lynparza) and rucaparib (Rubraca) to treat some men with metastatic prostate cancer. last dose of study drug. Read more about Pfizer, Moderna vaccines may vanquish Covid today, cancer tomorrow on Business Standard. and progressed on at least 1 novel hormonal agent (enzalutamide and/or abiraterone Dive Brief: Pfizer and Astellas Pharma released data Monday showing a combination of Xtandi and androgen deprivation therapy (ADT) significantly reduced the risk of death or radiographic progression by 61% compared to ADT alone in a certain type of prostate cancer. A minimum of 3 rising PSA values with an interval of at least 1 week between determinations. abnormal mammogram ... médico jefe de Pfizer. Just in time for the holiday season, Arvinas’ lead protein degraders delivered promising early results in patients with hard-to-treat breast or prostate cancer. Pfizer Oncology is striving to change the trajectory of cancer. 6 months as assessed by the investigator. 15. Today, Pfizer Oncology has an industry-leading portfolio of 22 approved innovative cancer medicines and biosimilars across more than 30 indications, including breast, prostate, kidney and lung cancers, as well as leukemia and melanoma. DNA damage repair deficiency as assessed centrally by a gene mutation biomarker panel While tumors discovered at an early stage can often be completely removed by surgery and radiation therapy, the prospects of successful treatment are reduced if the cancer has further metastasized. In our studies, progression was defined as the cancer getting worse, as measured by scans, or if the patient died for any reason. ng/mL) if qualifying solely by PSA progression. ATLANTA, Jan. 27, 2020 /PRNewswire/ -- The American Cancer Society and Pfizer have approved grants totaling more than $2.5 million in nine communities focused on reducing racial disparities and helping optimize outcomes for women facing a breast cancer diagnosis. Treatment with any concurrent cytotoxic chemotherapy or investigational drug(s) within 4 weeks or 5 half lives of the drug (whichever is longer) before Day 1 and/or during study participation. memory loss. 3. their family members, site staff members otherwise supervised by the investigator, or treatment of metastatic CRPC, irrespective of prior NHT treatment for non castrate At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. 15. 11. ESSA's Novel Prostate Cancer Treatment In Clinical Trial: Pfizer Is New Lead Investor Aug. 19, 2020 11:48 AM ET ESSA Pharma Inc. (EPIX) ARVN PFE 9 Comments 4 Likes Steven Goldman Westmead, New South Wales, 2145, Australia. Pfizer Inc. confirmed that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application to treat prostate cancer. Today, Pfizer Oncology has an industry-leading portfolio of 22 approved innovative cancer medicines and biosimilars across more than 30 indications, including breast, prostate, kidney and lung cancers, as well as leukemia and melanoma. abdominal pain. (Bloomberg) --Myovant Inc. soared after it agreed to collaborate with Pfizer Inc. on developing and commercializing a prostate cancer drug in a deal worth as much as $4.2 billion. Previous treatment with 1 or 2 chemotherapy regimens including at least 1 taxane-based regimen for metastatic (non castrate or castrate) prostate cancer. Consent to a saliva sample collection for a germline comparator, unless prohibited by local regulations or ethics committee (EC) decision. Therapeutic Modalities and Technology Platforms, Small Molecule Product & Process Development, Maintaining Emotional Well-Being During COVID-19, Coronavirus disease (COVID-19) Scientific Resources, Meet our new Chief Patient Officer, Dr. Dara Richardson-Heron, Creating Cures Through Facility Investments, A Study of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Prostate Cancer, Multimodality Phase II Study in Prostate Cancer, Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer, Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer, https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d…, International Committee of Medical Journal Editors, TALAPRO-1: A PHASE 2, OPEN-LABEL, RESPONSE RATE STUDY OF TALAZOPARIB IN MEN WITH DNA REPAIR DEFECTS AND METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO PREVIOUSLY RECEIVED TAXANE-BASED CHEMOTHERAPY AND PROGRESSED ON AT LEAST 1 NOVEL HORMONAL AGENT (ENZALUTAMIDE AND/OR ABIRATERONE ACETATE/PREDNISONE). ; The partnered companies had announced the success of the Phase 3 ARCHES study last December. 5. Prior diagnosis of myelodysplastic syndrome or acute myeloid leukemia. 11. “It increases the target market size by perhaps more than double,” Evercore ISI analyst Umer Raffat said. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. Bilateral orchiectomy or ongoing androgen deprivation therapy with a gonadotropin-releasing hormone (GnRH) agonist/antagonist (surgical or medical castration). This information—including product information—is intended only for residents of the United States. The screening central laboratory PSA value must be ? Pfizer is pinning its growth on approvals and success of 15 drugs, including Xtandi and breast cancer drug Ibrance, over the next five years. Men in each study either had surgery to lower testosterone or were taking hormone therapy. Interested in learning more about clinical trials? to assess the efficacy and safety of talazoparib in men with DNA repair defects metastatic day 1 for patients receiving these therapies. Analysts said the early success of the trial, which was originally set to be completed in 2019, validates Pfizer’s decision to buy Medivation. Fertile male subjects who are unwilling or unable to use a highly effective method of with the interpretation of study results and, in the judgment of the investigator, Meningitis. ... site staff members otherwise supervised by the investigator, or patients who are Pfizer employees, including their family members, directly involved in the conduct of the study. Bone disease progression defined by PCWG3 with 2 or more new metastatic lesions on bone scan. Please see the references below: 2. Prior treatment with a PARP inhibitor, cyclophosphamide, or mitoxantrone chemotherapy. Analysis of the genomic landscape of prostate cancer has identified different molecular subgroups with relevance for novel or existing targeted therapies. meningitis vaccine. months after last dose of study drug when having sex with a non pregnant female Questions about a trial? 4. Our strong pipeline—one of the most robust in the industry—includes biologics, small molecules, immunotherapies, and biosimilars, and is centered on exploring a wide array of approaches across many tumor types. Any other acute or chronic medical or psychiatric condition (concurrent disease, infection, or comorbidity) that interferes with ability to participate in the study, causes undue risk, or complicates the interpretation of data, in the opinion of the investigator or sponsor, including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study. The grants, funded by Pfizer Global Medical Grants and overseen by the American Cancer Society, are the first in … castration-resistant prostate cancer (CRPC) who previously received taxane-based chemotherapy Investigator site staff members directly involved in the conduct of the study and Radiation therapy within 3 weeks (within 2 weeks, if single fraction of radiotherapy) before day 1. The Prostate Cancer Foundation (PCF) and Pfizer, Inc. are proud to announce the PCF-Pfizer Global Challenge Awards, a competitive, peer-reviewed Investigator Sponsored Research (ISR) grants program. Symptomatic or impending spinal cord compression or cauda equina syndrome. The screening central laboratory PSA value must be ≥ 2 μg/L (2 A highly effective form of See here for a complete list of exchanges and delays. through 4 months after last dose of study drug. In prostate cancer, the androgen receptor (AR) is a key driver of progression.5 XTANDI is an AR-binding inhibitor, which works by preventing testosterone from binding to prostate cancer cells.2 XTANDI is thought to act on multiple steps of ... ABOUT THE ASTELLAS/PFIZER COLLABORATION 1. 2 ?g/L (2 ng/mL) if qualifying solely by PSA progression. Use of systemic chemotherapeutic (including but not limited to taxanes), hormonal, biologic, or radionuclide therapy for treatment of metastatic prostate cancer (other than approved bone targeting agents and GnRH agonist/antagonist) or any other investigational agent within 4 weeks before day 1. Myovant Inc. soared after it agreed to collaborate with Pfizer Inc. on developing and commercializing a prostate cancer drug in a deal worth as much as $4.2 billion. XTANDI has been studied in men with advanced prostate cancer. meditation and stress. Sorry, you need to enable JavaScript to visit this website. Bilateral orchiectomy or ongoing androgen deprivation therapy with a Pfizer Inc. (NYSE: PFE ) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") have announced final results from the overall survival (OS) analysis of the Phase 3 PROSPER trial, which evaluated XTANDI ® (enzalutamide) plus androgen deprivation therapy (ADT) versus placebo plus ADT in men with non-metastatic castration-resistant prostate cancer (nmCRPC). The purpose of this international, phase 2, open-label, response rate study of talazoparib is to assess the efficacy and safety of talazoparib in men with DNA repair defects metastatic castration-resistant prostate cancer (CRPC) who previously received taxane-based chemotherapy and progressed on at least 1 novel hormonal agent (enzalutamide and/or abiraterone acetate/prednisone). Previous treatment with 1 or 2 chemotherapy regimens including at least 1 taxane-based 4. Must agree not to donate sperm from the first dose of study drug to 4 months after the Any other acute or chronic medical or psychiatric condition (concurrent disease, The disease, disorder, syndrome, illness, or injury that is being studied. carvedilol, clarithromycin, cobicistat, darunavir, dronedarone, erythromycin, Bisphosphonate or denosumab dosage must have been stable for at least 4 weeks before in the conduct of the study. The Pfizer/BioNTech vaccine and the Moderna vaccine do not contain a live virus, so you can’t catch COVID-19 from these vaccines and they are safe for men having treatment for prostate cancer… Bone disease progression defined by Prostate Cancer Working Group 3 (PCWG3) with 2 or more new metastatic bone lesions on a whole body radionuclide bone scan. Able to swallow the study drug, have no known intolerance to study drugs or 16. Myovant shares soar 27% on news of Pfizer prostate cancer drug collaboration worth up to $4.2 billion Published: Dec. 29, 2020 at 6:05 a.m. Pfizer/Astellas’ prostate cancer treatment Xtandi (enzalutamide) is also a prominent market competitor, with approvals in nmCRPC, mCSPC and metastatic castration-resistant prostate cancer (mCRPC). The report referring to the Prostate Cancer Therapeutics Drugs Market Report is one of the most comprehensive and with key impaction additions designed for the buyers. Major surgery within 2 weeks before day 1. ATLANTA, March 3, 2021 /PRNewswire/ -- The American Cancer Society and Pfizer Global Medical Grants are collaborating and have awarded a new competitive grant opportunity focused on addressing prostate cancer disparities impacting Black men. Myovant Sciences (MYOV) and Pfizer enter collaboration agreement to develop and commercialize relugolix monotherapy and combination regimen for prostate cancer and uterine fibroids, respectively. 1.73 nmol/L (50 ng/dL) at screening. and the sponsor. Pfizer Oncology is striving to change the trajectory of cancer. Orgovyx (relugolix), which will become available for advanced prostate cancer patients in the US, offers a new option that enables at-home administration.. Prostate Cancer UK Online Community Speak to a Specialist Nurse 0800 074 8383 The U.K. company's prostate cancer drug … ESSA's Novel Prostate Cancer Treatment In Clinical Trial: Pfizer Is New Lead Investor Aug. 19, 2020 11:48 AM ET ESSA Pharma Inc. (EPIX) ARVN PFE 9 Comments 4 Likes Steven Goldman In this particularly personal episode of The Doctors , Dr. Freda Lewis-Hall shares the signs & symptoms of prostate cancer- the second most common cancer in men worldwide.
Tv2 Magyar Online, Elemental Shaman Pvp Icy, Mountainbike Test Bis 400 Euro, Adjektive Mit T, Rücksendeetikett Vorlage Word,